BAM
RIGL icon

Blueshift Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Blueshift Asset Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,577
Closed -$55K – 1041
2020
Q4 		$55K Buy
+1,577
New +$45.7K 0.01% 659

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blueshift Asset Management's RIGL Position: Q1 2021 in Review

Blueshift Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2021, closing a stake of 1,577 shares — an estimated $55K sold.

Blueshift Asset Management first reported a position in RIGL in Q4 2020 and held it in 1 quarter. The position peaked at $55K in Q4 2020. 152 funds tracked by Wall St. Rank hold RIGL as of Q1 2021.

  • Blueshift Asset Management reported no remaining Rigel Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 1,577 Rigel Pharmaceuticals shares in Q1 2021, an estimated $55K.
  • Blueshift Asset Management first reported a position in Rigel Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Blueshift Asset Management's Rigel Pharmaceuticals position peaked at $55K in Q4 2020.
  • 152 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2021.

Based on Blueshift Asset Management's 13F filing for Q1 2021, filed 6 May 2021.